John A. Kollins serves as President, Chief Executive Officer, Director of the Company. Mr. Kollins has served as a member of our Board and as our President and Chief Executive Officer since July 2016. Since 1989, Mr. Kollins has worked in the biopharmaceutical industry in Director, CEO, executive management, business and corporate development, and commercial roles. He has extensive experience working in CNS-focused biopharmaceutical companies, including Transcept Pharmaceuticals, where he served from June 2012 to October 2014 as Chief Business Officer, Renovis, Elan Pharmaceuticals and Athena Neurosciences. From November 2014 until co-founding Satsuma Pharmaceuticals in July 2016, Mr. Kollins was Managing Director of Parnassus Advisors, LLC, which he founded to provide strategic consulting and corporate development services to biopharmaceutical companies. Mr. Kollins earned an M.B.A. from the University of Virginia’s Darden School and an engineering degree from Duke University.
As the President、 Chief Executive Officer、 Director of Satsuma Pharmaceuticals, the total compensation of John Kollins at Satsuma Pharmaceuticals is 1,368,100$. There are no executives at Satsuma Pharmaceuticals getting paid more.
John Kollins is 57, he's been the President、 Chief Executive Officer、 Director of Satsuma Pharmaceuticals since 2018. There are 7 older and 9 younger executives at Satsuma Pharmaceuticals. The oldest executive at Satsuma Pharmaceuticals, Inc. is Alan C. Mendelson J.D., 71, who is the Sec..
Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over 2,307,500$ worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth 106,923,937$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Capital Management, L.P.Ra ...、Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of 2,050,940$. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth 20,068,759$.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include: